Prevalence, mechanisms, and management of cancer-related cognitive impairment

References

• Abraham, J., Haut, M.W., Moran, M.T., Filburn, S., Lemiuex, S. & Kuwabara, H. (2008). Adjuvant chemotherapy for breast cancer: Effects on cerebral white matter seen in diffusion tensor imaging. Clinical Breast Cancer, 8, 88–91.
   PubMed Web of Science ®Google Scholar
• ACS. (2013). Cancer Facts and Figures 2013. Atlanta: American Cancer Society.
   Google Scholar
• Ahles, T.A., Root, J.C. & Ryan, E.L. (2012). Cancer- and cancer treatment-associated cognitive change: An update on the state of the science. Journal of Clinical Oncology, 30, 3675–3686.
   PubMed Web of Science ®Google Scholar
• Ahles, T.A. & Saykin, A.J. (2007). Candidate mechanisms for chemotherapy-induced cognitive changes. Nature Reviews Cancer, 7, 192–201.
   PubMed Web of Science ®Google Scholar
• Ahles, T.A., Saykin, A.J., Furstenberg, C.T., Cole, B., Mott, L.A., Skalla, K., … Silberfarb, P.M. (2002). Neuropsychologic impact of standard-dose systemic chemotherapy in long- term survivors of breast cancer and lymphoma. Journal of Clinical Oncology, 20, 485–493.
   PubMed Web of Science ®Google Scholar
• Ahles, T.A., Saykin, A.J., McDonald, B.C., Furstenberg, C.T., Cole, B.F., Hanscom, B.S., … Kaufman, P.A. (2008). Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Research and Treament, 110, 143–152. doi: 10.1007/s10549-007-9686-5
   PubMed Web of Science ®Google Scholar
• Ahles, T.A., Saykin, A.J., McDonald, B.C., Li, Y., Furstenberg, C.T., Hanscom, B.S., … Kaufman, P.A. (2010). Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: Impact of age and cognitive reserve. Journal of Clinical Oncology, 28, 4434–4440. doi: 10.1200/JCO.2009.27.0827
   PubMed Web of Science ®Google Scholar
• Ahles, T.A., Saykin, A.J., Noll, W.W., Furstenberg, C.T., Guerin, S., Cole, B. & Mott, L.A. (2003). The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psycho-Oncology, 12, 612–619. doi: 10.1002/pon.742
   PubMed Web of Science ®Google Scholar
• Barton, D.L., Burger, K., Novotny, P.J., Fitch, T.R., Kohli, S., Soori, G., … Loprinzi, C.L. (2013). The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9. Supportive Care in Cancer, 21, 1185–1192. doi: 10.1007/s00520-012-1647-9
   PubMedGoogle Scholar
• Bender, C.M., Sereika, S.M., Berga, S.L., Vogel, V.G., Brufsky, A.M., Paraska, K.K. & Ryan, C.M. (2006). Cognitive impairment associated with adjuvant therapy in breast cancer. Psycho-Oncology, 15, 422–430. doi: 10.1002/pon.964
   PubMed Web of Science ®Google Scholar
• Biglia, N., Bounous, V.E., Malabaila, A., Palmisano, D., Torta, D.M., D’Alonzo, M., … Torta, R. (2012). Objective and self-reported cognitive dysfunction in breast cancer women treated with chemotherapy: A prospective study. European Journal of Cancer Care, 21, 485–492. doi: 10.1111/ j.1365-2354. 2011.01320.x
   Google Scholar
• Bradley, C.J., Neumark, D., Bednarek, H.L. & Schenk, M. (2005). Short-term effects of breast cancer on labor market attachment: Results from a longitudinal study. Journal of Health Economics, 24, 137–160. doi: S0167-6296(04)00098-0 p.10.1016/j.jhealeco.2004.07.003
   PubMed Web of Science ®Google Scholar
• Brezden, C.B., Phillips, K.A., Abdolell, M., Bunston, T. & Tannock, I.F. (2000). Cognitive function in breast cancer patients receiving adjuvant chemotherapy. Journal of Clinical Oncology, 18, 2695–2701.
   PubMed Web of Science ®Google Scholar
• Brown, M.S., Stemmer, S.M., Simon, J.H., Stears, J.C., Jones, R.B., Cagnoni, P.J. & Sheeder, J.L. (1998). White matter disease induced by high-dose chemotherapy: Longitudinal study with MR imaging and proton spectroscopy. American Journal of Neuroradiology, 19, 217–221.
   PubMed Web of Science ®Google Scholar
• Bruno, J., Hosseini, S.M. & Kesler, S. (2012). Altered resting state functional brain network topology in chemotherapy-treated breast cancer survivors. Neurobiology of Disease, 48, 329–338. doi: 10.1016/j.nbd.2012.07.009
   PubMedGoogle Scholar
• Castellon, S.A., Ganz, P.A., Bower, J.E., Petersen, L., Abraham, L. & Greendale, G.A. (2004). Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. Journal of Clinical and Experimental Neuropsychology, 26, 955–969.
   PubMed Web of Science ®Google Scholar
• Cleeland, C.S., Bennett, G.J., Dantzer, R., Dougherty, P.M., Dunn, A.J., Meyers, C.A., … Lee, B.N. (2003). Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer, 97, 2919–2925. doi: 10.1002/cncr.11382
   PubMed Web of Science ®Google Scholar
• Collins, B., Mackenzie, J., Stewart, A., Bielajew, C. & Verma, S. (2009). Cognitive effects of chemotherapy in post-menopausal breast cancer patients 1 year after treatment. Psycho-oncology, 18, 134–143. doi: 10.1002/pon.1379
   PubMed Web of Science ®Google Scholar
• Conroy, S.K., McDonald, B.C., Ahles, T.A., West, J.D. & Saykin, A.J. (2013). Chemotherapy-induced amenorrhea: A prospective study of brain activation changes and neurocognitive correlates. Brain Imaging and Behavior. doi: 10.1007/s11682-013-9240-5
   PubMedGoogle Scholar
• Correa, D.D. & Hess, L.M. (2012). Cognitive function and quality of life in ovarian cancer. Gynecologic Oncology, 124, 404–409. doi: 10.1016/j.ygyno.2011.11.005
   PubMed Web of Science ®Google Scholar
• Correa, D.D., Zhou, Q., Thaler, H.T., Maziarz, M., Hurley, K. & Hensley, M.L. (2010). Cognitive functions in long- term survivors of ovarian cancer. Gynecologic Oncology, 119, 366–369. doi: 10.1016/j.ygyno.2010.06.023
   PubMedGoogle Scholar
• Dantzer, R. & Kelley, K.W. (2007). Twenty years of research on cytokine-induced sickness behavior. Brain, Behavior, and Immunity, 21, 153–160. doi: 10.1016/j.bbi.2006.09.006
   PubMed Web of Science ®Google Scholar
• Debess, J., Riis, J.O., Engebjerg, M.C. & Ewertz, M. (2010). Cognitive function after adjuvant treatment for early breast cancer: A population-based longitudinal study. Breast Cancer Research and Treatment, 121, 91–100. doi: 10.1007/s10549- 010-0756-8
   PubMed Web of Science ®Google Scholar
• Deprez, S., Amant, F., Smeets, A., Peeters, R., Leemans, A., Van Hecke, W., … Sunaert, S. (2012). Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. Journal of Clinical Oncology, 30, 274–281. doi: 10.1200/JCO.2011.36.8571
   PubMed Web of Science ®Google Scholar
• Deprez, S., Amant, F., Yigit, R., Porke, K., Verhoeven, J., Van den Stock, J., … Sunaert, S. (2011). Chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning in breast cancer patients. Human Brain Mapping, 32, 480–493. doi: 10.1002/hbm.21033
   PubMed Web of Science ®Google Scholar
• de Ruiter, M.B., Reneman, L., Boogerd, W., Veltman, D.J., Caan, M., Douaud, G., … Schagen, S.B. (2012). Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: Converging results from multimodal magnetic resonance imaging. Human Brain Mapping, 33, 2971–2983. doi: 10.1002/hbm.21422
   PubMed Web of Science ®Google Scholar
• de Ruiter, M.B., Reneman, L., Boogerd, W., Veltman, D.J., van Dam, F.S., Nederveen, A.J., … Schagen, S.B. (2011). Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. Human Brain Mapping, 32, 1206–1219. doi: 10.1002/hbm.21102
   PubMed Web of Science ®Google Scholar
• Dietrich, J., Han, R., Yang, Y., Mayer-Proschel, M. & Noble, M. (2006). CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. Journal of Biology, 5, 22. doi: jbiol50 [pii]10.1186/jbiol50
   PubMedGoogle Scholar
• Dumas, J.A., Makarewicz, J., Schaubhut, G.J., Devins, R., Albert, K., Dittus, K. & Newhouse, P.A. (2013). Chemotherapy altered brain functional connectivity in women with breast cancer: A pilot study. Brain Imaging and Behavior. doi: 10.1007/s11682-013-9244-1
   PubMedGoogle Scholar
• Fan, H.G., Houede-Tchen, N., Yi, Q.L., Chemerynsky, I., Downie, F.P., Sabate, K. & Tannock, I.F. (2005). Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study. Journal of Clinical Oncology, 23, 8025–8032. doi: 10.1200/JCO.2005.01.6550
   PubMed Web of Science ®Google Scholar
• Fardell, J.E., Vardy, J. & Johnston, I.N. (2013). The short and long term effects of docetaxel chemotherapy on rodent object recognition and spatial reference memory. Life Sciences. doi: 10.1016/j.lfs.2013.05.006
   PubMedGoogle Scholar
• Fardell, J.E., Vardy, J., Johnston, I.N. & Winocur, G. (2011). Chemotherapy and cognitive impairment: Treatment options. Clinical Pharmacology and Therapeutics, 90, 366–376. doi: 10.1038/clpt.2011.112
   PubMed Web of Science ®Google Scholar
• Fardell, J.E., Vardy, J., Logge, W. & Johnston, I. (2010). Single high dose treatment with methotrexate causes long-lasting cognitive dysfunction in laboratory rodents. Pharmacology, Biochemistry, and Behavior, 97, 333–339. doi: 10.1016/j.pbb.2010.08.019
   PubMedGoogle Scholar
• Fardell, J.E., Vardy, J., Shah, J.D. & Johnston, I.N. (2012). Cognitive impairments caused by oxaliplatin and 5-fluorouracil chemotherapy are ameliorated by physical activity. Psychopharmacology, 220, 183–193. doi: 10.1007/s00213-011-2466-2
   PubMed Web of Science ®Google Scholar
• Ferguson, R.J., McDonald, B.C., Rocque, M.A., Furstenberg, C.T., Horrigan, S., Ahles, T.A. & Saykin, A.J. (2012). Development of CBT for chemotherapy-related cognitive change: Results of a waitlist control trial. Psycho-Oncology, 21, 176–186. doi: 10.1002/pon.1878
   PubMed Web of Science ®Google Scholar
• Ferguson, R.J., McDonald, B.C., Saykin, A.J. & Ahles, T.A. (2007). Brain structure and function differences in monozygotic twins: Possible effects of breast cancer chemotherapy. Journal of Clinical Oncology, 25, 3866–3870. doi: 10.1200/JCO.2007.10.8639
   PubMed Web of Science ®Google Scholar
• Ganz, P.A., Bower, J.E., Kwan, L., Castellon, S.A., Silverman, D.H., Geist, C., … Cole, S.W. (2013). Does tumor necrosis factor-alpha (TNF-alpha) play a role in post-chemotherapy cerebral dysfunction?Brain, Behavior, and Immunity, 30, S99–108. doi: 10.1016/j.bbi.2012.07.015
   PubMed Web of Science ®Google Scholar
• Han, R., Yang, Y.M., Dietrich, J., Luebke, A., Mayer-Proschel, M. & Noble, M. (2008). Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system. Journal of Biology, 7, 12. doi: jbiol69 [pii]10.1186/jbiol69
   PubMedGoogle Scholar
• Hedayati, E., Alinaghizadeh, H., Schedin, A., Nyman, H. & Albertsson, M. (2012). Effects of adjuvant treatment on cognitive function in women with early breast cancer. European Journal of Oncology Nursing, 16, 315–322. doi: 10.1016/j.ejon.2011.07.006
   PubMed Web of Science ®Google Scholar
• Helal, G.K., Aleisa, A.M., Helal, O.K., Al-Rejaie, S.S., Al-Yahya, A.A., Al-Majed, A.A. & Al-Shabanah, O.A. (2009). Metallothionein induction reduces caspase-3 activity and TNFalpha levels with preservation of cognitive function and intact hippocampal neurons in carmustine-treated rats. Oxidative Medicine and Cellular Longevity, 2, 26–35.
   PubMedGoogle Scholar
• Hermelink, K., Henschel, V., Untch, M., Bauerfeind, I., Lux, M.P. & Munzel, K. (2008). Short-term effects of treatment-induced hormonal changes on cognitive function in breast cancer patients: Results of a multicenter, prospective, longitudinal study. Cancer, 113, 2431–2439. doi: 10.1002/cncr.23853
   PubMed Web of Science ®Google Scholar
• Hermelink, K., Untch, M., Lux, M.P., Kreienberg, R., Beck, T., Bauerfeind, I. & Munzel, K. (2007). Cognitive function during neoadjuvant chemotherapy for breast cancer: Results of a prospective, multicenter, longitudinal study. Cancer, 109, 1905–1913. doi: 10.1002/cncr.22610
   PubMed Web of Science ®Google Scholar
• Hosseini, S.M. & Kesler, S.R. (2013). Multivariate pattern analysis of fMRI in breast cancer survivors and healthy women. Journal of the International Neuropsychological Society 18:1–11. [Epub ahead of print].
   Google Scholar
• Hosseini, S.M., Koovakkattu, D. & Kesler, S.R. (2012). Altered small-world properties of gray matter networks in breast cancer. BMC Neurology, 12, 28. doi: 10.1186/1471-2377-12-28
   PubMed Web of Science ®Google Scholar
• Hsieh, T.C., Wu, Y.C., Yen, K.Y., Chen, S.W. & Kao, C.H. (2013). Early changes in brain FDG metabolism during anticancer therapy in patients with pharyngeal cancer. Journal of Neuroimaging. doi: 10.1111/jon.12006
   PubMedGoogle Scholar
• Hurria, A., Rosen, C., Hudis, C., Zuckerman, E., Panageas, K.S., Lachs, M.S., … Holland, J. (2006). Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: A pilot prospective longitudinal study. Journal of the American Geriatrics Society, 54, 925–931. doi: 10.1111 /j.1532-5415.2006.00732.x
   PubMed Web of Science ®Google Scholar
• Inagaki, M., Yoshikawa, E., Matsuoka, Y., Sugawara, Y., Nakano, T., Akechi, T., … Uchitomi, Y. (2007). Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer, 109, 146–156. doi: 10.1002/cncr.22368
   PubMed Web of Science ®Google Scholar
• Janelsins, M.C., Kohli, S., Mohile, S.G., Usuki, K., Ahles, T.A. & Morrow, G.R. (2011). An update on cancer- and chemotherapy-related cognitive dysfunction: Current status. Seminars in Oncology, 38, 431–438. doi: 10.1053/j.seminoncol.2011. 03.014
   PubMed Web of Science ®Google Scholar
• Janelsins, M.C., Mustian, K.M., Palesh, O.G., Mohile, S.G., Peppone, L.J., Sprod, L.K., … Morrow, G.R. (2012). Differential expression of cytokines in breast cancer patients receiving different chemotherapies: Implications for cognitive impairment research. Supportive Care in Cancer, 20, 831–839. doi: 10.1007/s00520-011-1158-0
   PubMed Web of Science ®Google Scholar
• Janelsins, M.C., Roscoe, J.A., Berg, M.J., Thompson, B.D., Gallagher, M.J., Morrow, G.R., … Gross, R.A. (2010). IGF-1 partially restores chemotherapy-induced reductions in neural cell proliferation in adult C57BL/6 mice. Cancer Investigation, 28, 544–553. doi: 10.3109/0735790 0903405942
   PubMed Web of Science ®Google Scholar
• Jansen, C.E., Cooper, B.A., Dodd, M.J. & Miaskowski, C.A. (2011). A prospective longitudinal study of chemotherapy-induced cognitive changes in breast cancer patients. Supportive Care in Cancer, 19, 1647–1656. doi: 10.1007/s00520-010-0997-4
   PubMed Web of Science ®Google Scholar
• Jenkins, V., Shilling, V., Deutsch, G., Bloomfield, D., Morris, R., Allan, S., … Winstanley, J. (2006). A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. British Journal of Cancer, 94, 828–834. doi: 6603029 [pii]10.1038/sj.bjc.6603029
   PubMed Web of Science ®Google Scholar
• Joshi, G., Hardas, S., Sultana, R., St Clair, D.K., Vore, M. & Butterfield, D.A. (2007). Glutathione elevation by gamma-glutamyl cysteine ethyl ester as a potential therapeutic strategy for preventing oxidative stress in brain mediated by in vivo administration of adriamycin: Implication for chemobrain. Journal of Neuroscience Research, 85, 497–503. doi: 10.1002/jnr.21158
   PubMed Web of Science ®Google Scholar
• Kesler, S. (in press). Default mode network as a potential biomarker of chemotherapy-related brain injury and altered brain aging. Neurobiology of Aging.
   Google Scholar
• Kesler, S., Hadi Hosseini, S.M., Heckler, C., Janelsins, M., Palesh, O., Mustian, K. & Morrow, G. (2013a). Cognitive training for improving executive function in chemotherapy-treated breast cancer survivors. Clinical Breast Cancer, 13, 299–306. doi: 10.1016/j.clbc.2013.02.004
   PubMed Web of Science ®Google Scholar
• Kesler, S., Janelsins, M., Koovakkattu, D., Palesh, O., Mustian, K., Morrow, G. & Dhabhar, F.S. (2013b). Reduced hippocampal volume and verbal memory performance associated with interleukin-6 and tumor necrosis factor-alpha levels in chemotherapy-treated breast cancer survivors. Brain, Behavior, and Immunity, 30, S109–116. doi: 10.1016/j.bbi.2012.05.017
   PubMed Web of Science ®Google Scholar
• Kesler, S.R., Bennett, F.C., Mahaffey, M.L. & Spiegel, D. (2009). Regional brain activation during verbal declarative memory in metastatic breast cancer. Clinical Cancer Research, 15, 6665–6673. doi: 10.1158/1078-0432.CCR-09-1227
   PubMed Web of Science ®Google Scholar
• Kesler, S.R., Kent, J.S. & O’Hara, R. (2011). Prefrontal cortex and executive function impairments in primary breast cancer. Archives of Neurology, 68, 1447–1453. doi: 10.1001/archneurol. 2011.245
   PubMed Web of Science ®Google Scholar
• Kesler, S.R., Watson, C., Koovakkattu, D., Lee, C., O’Hara, R., Mahaffey, M.L. & Wefel, J.S. (2013a). Elevated prefrontal myo-inositol and choline following breast cancer chemotherapy. Brain Imaging and Behavior. doi: 10.1007/s11682-013-9228-1
   PubMedGoogle Scholar
• Kesler, S.R., Wefel, J.S., Hosseini, S.M., Cheung, M., Watson, C.L. & Hoeft, F. (2013b). Default mode network connectivity distinguishes chemotherapy-treated breast cancer survivors from controls. Proceedings of the National Academy of the Sciences of the United States of America, 110, 11600–11605. doi: 10.1073/pnas.1214551110
   PubMedGoogle Scholar
• Kohli, S., Fisher, S.G., Tra, Y., Adams, M.J., Mapstone, M.E., Wesnes, K.A., … Morrow, G.R. (2009). The effect of modafinil on cognitive function in breast cancer survivors. Cancer, 115, 2605–2616. doi: 10.1002/cncr.24287
   PubMed Web of Science ®Google Scholar
• Kohli, S., Griggs, J.J., Roscoe, J.A., Jean-Pierre, P., Bole, C., Mustian, K.M., … Morrow, G.R. (2007). Self-reported cognitive impairment in patients with cancer. Journal of Oncology Practice, 3, 54–59. doi: 10.1200/JOP.0722001
   PubMedGoogle Scholar
• Konat, G.W., Kraszpulski, M., James, I., Zhang, H.T. & Abraham, J. (2008). Cognitive dysfunction induced by chronic administration of common cancer chemotherapeutics in rats. Metabolic Brain Disease, 23, 325–333. doi: 10.1007/s11011-008-9100-y
   PubMed Web of Science ®Google Scholar
• Koppelmans, V., Breteler, M.M., Boogerd, W., Seynaeve, C., Gundy, C. & Schagen, S.B. (2012). Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. Journal of Clinical Oncology, 30, 1080–1086. doi: 10.1200/JCO.2011.37.0189
   PubMed Web of Science ®Google Scholar
• Korkaya, H., Liu, S. & Wicha, M.S. (2011). Breast cancer stem cells, cytokine networks, and the tumor microenvironment. Journal of Clinical Investigation, 121, 3804–3809. doi: 10.1172/JCI57099
   PubMed Web of Science ®Google Scholar
• Lai, J.S., Butt, Z., Wagner, L., Sweet, J.J., Beaumont, J.L., Vardy, J., … Cella, D. (2009). Evaluating the dimensionality of perceived cognitive function. Journal of Pain and Symptom Management, 37, 982–995. doi: 10.1016/j.jpainsymman. 2008.07.012
   PubMedGoogle Scholar
• Loef, M. & Walach, H. (2012). Fruit, vegetables and prevention of cognitive decline or dementia: A systematic review of cohort studies. Journal of Nutrition, Health and Aging, 16, 626–630.
   PubMed Web of Science ®Google Scholar
• Loef, M. & Walach, H. (2013). Midlife obesity and dementia: meta-analysis and adjusted forecast of dementia prevalence in the United States and China. Obesity, 21, E51–55. doi: 10.1002/oby.20037
   Web of Science ®Google Scholar
• Lower, E.E., Fleishman, S., Cooper, A., Zeldis, J., Faleck, H., Yu, Z. & Manning, D. (2009). Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: A randomized clinical trial. Journal of Pain and Symptom Management, 38, 650–662. doi: 10.1016/j.jpainsymman. 2009.03.011
   PubMed Web of Science ®Google Scholar
• Lundorff, L.E., Jonsson, B.H. & Sjogren, P. (2009). Modafinil for attentional and psychomotor dysfunction in advanced cancer: A double-blind, randomised, cross-over trial. Palliative Medicine, 23, 731–738. doi: 10.1177/0269216309106872
   PubMed Web of Science ®Google Scholar
• Lyons, L., ELBeltagy, M., Bennett, G. & Wigmore, P. (2012). Fluoxetine counteracts the cognitive and cellular effects of 5-fluorouracil in the rat hippocampus by a mechanism of prevention rather than recovery. PLOS ONE, 7, e30010. doi: 10.1371/journal.pone.0030010
   PubMed Web of Science ®Google Scholar
• Lyons, L., ELBeltagy, M., Umka, J., Markwick, R., Startin, C., Bennett, G. & Wigmore, P. (2011). Fluoxetine reverses the memory impairment and reduction in proliferation and survival of hippocampal cells caused by methotrexate chemotherapy. Psychopharmacology, 215, 105–115. doi: 10.1007/s00213-010-2122-2
   PubMed Web of Science ®Google Scholar
• Mar Fan, H.G., Clemons, M., Xu, W., Chemerynsky, I., Breunis, H., Braganza, S. & Tannock, I.F. (2008). A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer. Supportive Care in Cancer, 16, 577–583. doi: 10.1007/s00520-007-0341-9
   PubMed Web of Science ®Google Scholar
• McAllister, T.W., Ahles, T.A., Saykin, A.J., Ferguson, R.J., McDonald, B.C., Lewis, L.D., … Rhodes, C.H. (2004). Cognitive effects of cytotoxic cancer chemotherapy: Predisposing risk factors and potential treatments. Current Psychiatry Reports, 6, 364–371.
   PubMedGoogle Scholar
• McDonald, B.C., Conroy, S.K., Ahles, T.A., West, J.D. & Saykin, A.J. (2010). Gray matter reduction associated with systemic chemotherapy for breast cancer: A prospective MRI study. Breast Cancer Research and Treatment, 123, 819–828. doi: 10.1007/s10549-010-1088-4
   PubMed Web of Science ®Google Scholar
• McDonald, B.C., Conroy, S.K., Ahles, T.A., West, J.D. & Saykin, A.J. (2012). Alterations in brain activation during working memory processing associated with breast cancer and treatment: A prospective functional magnetic resonance imaging study. Journal of Clinical Oncology, 30, 2500–2508. doi: 10.1200/JCO.2011.38.5674
   PubMedGoogle Scholar
• McDonald, B.C., Conroy, S.K., Smith, D.J., West, J.D. & Saykin, A.J. (2013). Frontal gray matter reduction after breast cancer chemotherapy and association with executive symptoms: A replication and extension study. Brain, Behavior, and Immunity, 30, S117–125. doi: 10.1016/j.bbi.2012.05.007
   PubMed Web of Science ®Google Scholar
• Mehlsen, M., Pedersen, A.D., Jensen, A.B. & Zachariae, R. (2009). No indications of cognitive side-effects in a prospective study of breast cancer patients receiving adjuvant chemotherapy. Psycho-Oncology, 18, 248–257. doi: 10.1002/pon.1398
   PubMed Web of Science ®Google Scholar
• Meyers, C.A., Albitar, M. & Estey, E. (2005). Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer, 104, 788–793. doi: 10.1002/cncr.21234
   PubMed Web of Science ®Google Scholar
• Mills, P.J., Ancoli-Israel, S., Parker, B., Natarajan, L., Hong, S., Jain, S., … von Kanel, R. (2008). Predictors of inflammation in response to anthracycline-based chemotherapy for breast cancer. Brain, Behavior, and Immunity, 22, 98–104. doi: S0889-1591(07)00162-6 [pii]10.1016/j.bbi.2007.07.001
   PubMed Web of Science ®Google Scholar
• Morley, K.I. & Montgomery, G.W. (2001). The genetics of cognitive processes: Candidate genes in humans and animals. Behavior Genetics, 31, 511–531.
   PubMed Web of Science ®Google Scholar
• Morrow, G.R., Shelke, A.R., Roscoe, J.A., Hickok, J.T. & Mustian, K. (2005). Management of cancer-related fatigue. Cancer Investigation, 23, 229–239.
   PubMed Web of Science ®Google Scholar
• Mustian, K.M., Sprod, L.K., Janelsins, M., Peppone, L.J. & Mohile, S. (2012). Exercise recommendations for cancer-related fatigue, cognitive impairment, sleep problems, depression, pain, anxiety, and physical dysfunction: A review. Oncology and Hematology Review, 8, 81–88.
   PubMedGoogle Scholar
• Myers, J.S. (2012). Chemotherapy-related cognitive impairment: The breast cancer experience. Oncology Nursing Forum, 39(1), E31–40. doi: 10.1188/12.ONF.E31-E40
   PubMedGoogle Scholar
• Nelson, C.J., Lee, J.S., Gamboa, M.C. & Roth, A.J. (2008). Cognitive effects of hormone therapy in men with prostate cancer: A review. Cancer, 113, 1097–1106. doi: 10.1002/cncr.23658
   PubMed Web of Science ®Google Scholar
• Oh, B., Butow, P.N., Mullan, B.A., Clarke, S.J., Beale, P.J., Pavlakis, N., … Vardy, J. (2012). Effect of medical Qigong on cognitive function, quality of life, and a biomarker of inflammation in cancer patients: A randomized controlled trial. Supportive Care in Cancer, 20, 1235–1242. doi: 10.1007/s00520-011-1209-6
   PubMedGoogle Scholar
• Ouimet, L.A., Stewart, A., Collins, B., Schindler, D. & Bielajew, C. (2009). Measuring neuropsychological change following breast cancer treatment: an analysis of statistical models. Journal of Clinical and Experimental Neuropsychology, 31, 73–89. doi: 793717043 [pii]10.1080/13803390801992725
   PubMed Web of Science ®Google Scholar
• Palesh, O., Peppone, L., Innominato, P.F., Janelsins, M., Jeong, M., Sprod, L., … Mustian, K. (2012). Prevalence, putative mechanisms, and current management of sleep problems during chemotherapy for cancer. Nature and Science of Sleep, 4, 151–162. doi: 10.2147/NSS.S18895
   PubMedGoogle Scholar
• Palmer, J.L., Trotter, T., Joy, A.A. & Carlson, L.E. (2008). Cognitive effects of Tamoxifen in pre-menopausal women with breast cancer compared to healthy controls. Journal of Cancer Survivorship, 2, 275–282. doi: 10.1007/s11764-008-0070-1
   Google Scholar
• Paraska, K. & Bender, C.M. (2003). Cognitive dysfunction following adjuvant chemotherapy for breast cancer: Two case studies. Oncology Nursing Forum, 30, 473–478. doi: 10.1188/03.ONF.473-478
   PubMedGoogle Scholar
• Pomykala, K.L., Ganz, P.A., Bower, J.E., Kwan, L., Castellon, S.A., Mallam, S., … Silverman, D.H. (2013). The association between pro-inflammatory cytokines, regional cerebral metabolism, and cognitive complaints following adjuvant chemotherapy for breast cancer. Brain Imaging and Behavior. doi: 10.1007/s11682-013-9243-2
   Google Scholar
• Pusztai, L., Mendoza, T.R., Reuben, J.M., Martinez, M.M., Willey, J.S., Lara, J., … Hortobagyi, G.N. (2004). Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine, 25, 94–102.
   PubMed Web of Science ®Google Scholar
• Quesnel, C., Savard, J. & Ivers, H. (2009). Cognitive impairments associated with breast cancer treatments: Results from a longitudinal study. Breast Cancer Research and Treatment, 116, 113–123. doi: 10.1007/s10549-008-0114-2
   PubMed Web of Science ®Google Scholar
• Raffa, R.B. (2011). A proposed mechanism for chemotherapy-related cognitive impairment (‘chemo-fog’). Journal of Clinical Pharmacy and Therapeutics, 36, 257–259. doi: 10.1111/j.1365-2710.2010.01188.x
   PubMedGoogle Scholar
• Rego, S.L., Helms, R.S. & Dreau, D. (2013). Tumor necrosis factor-alpha-converting enzyme activities and tumor-associated macrophages in breast cancer. Immunologic Research.doi : 10.1007/s12026-013-8434-7
   Google Scholar
• Reid-Arndt, S.A. & Cox, C.R. (2012). Stress, coping and cognitive deficits in women after surgery for breast cancer. Journal of Clinical Psychology in Medical Settings, 19, 127–137. doi: 10.1007/s10880-011-9274-z
   PubMedGoogle Scholar
• Reid-Arndt, S.A., Matsuda, S. & Cox, C.R. (2012). Tai chi effects on neuropsychological, emotional, and physical functioning following cancer treatment: A pilot study. Complementary Therapies in Clinical Practice, 18, 26–30. doi: 10.1016/j.ctcp.2011.02.005
   PubMedGoogle Scholar
• Reid-Arndt, S.A., Yee, A., Perry, M.C. & Hsieh, C. (2009). Cognitive and psychological factors associated with early posttreatment functional outcomes in breast cancer survivors. Journal of Psychosocial Oncology, 27, 415–434. doi: 10.1080/07347330903183117
   PubMed Web of Science ®Google Scholar
• Reiriz, A.B., Reolon, G.K., Preissler, T., Rosado, J.O., Henriques, J.A., Roesler, R. & Schwartsmann, G. (2006). Cancer chemotherapy and cognitive function in rodent models: Memory impairment induced by cyclophosphamide in mice. Clinical Cancer Research, 12, 5000; author reply 5000-5001. doi: 10.1158/1078-0432.CCR-06-0138
   PubMed Web of Science ®Google Scholar
• Reuter-Lorenz, P.A. & Cimprich, B. (2013). Cognitive function and breast cancer: Promise and potential insights from functional brain imaging. Breast Cancer Research and Treatment, 137, 33–43. doi: 10.1007/s10549-012-2266-3
   PubMed Web of Science ®Google Scholar
• Ryan, J.L., Carroll, J.K., Ryan, E.P., Mustian, K.M., Fiscella, K. & Morrow, G.R. (2007). Mechanisms of cancer-related fatigue. Oncologist, 12, S22–34. doi: 10.1634/theoncologist.12-S1-22
   PubMed Web of Science ®Google Scholar
• Schagen, S.B., Boogerd, W., Muller, M.J., Huinink, W.T., Moonen, L., Meinhardt, W. & Van Dam, F.S. (2008). Cognitive complaints and cognitive impairment following BEP chemotherapy in patients with testicular cancer. Acta Oncologica, 47, 63–70. doi: 10.1080/02841860701518058
   PubMed Web of Science ®Google Scholar
• Schagen, S.B., Muller, M.J., Boogerd, W., Mellenbergh, G.J. & van Dam, F.S. (2006). Change in cognitive function after chemotherapy: A prospective longitudinal study in breast cancer patients. Journal of the National Cancer Institute, 98, 1742–1745. doi: 10.1093/jnci/djj470
   PubMed Web of Science ®Google Scholar
• Schilder, C.M., Eggens, P.C., Seynaeve, C., Linn, S.C., Boogerd, W., Gundy, C.M., … Schagen, S.B. (2009). Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: Cross-sectional findings from the neuropsychological TEAM-side study. Acta Oncologica, 48, 76–85. doi: 902183905 p. 10.1080/02841860802314738
   PubMed Web of Science ®Google Scholar
• Schilder, C.M., Seynaeve, C., Beex, L.V., Boogerd, W., Linn, S.C., Gundy, C.M., … Schagen, S.B. (2010). Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. Journal of Clinical Oncology, 28(8), 1294–1300. doi: JCO.2008.21.3553 p. 10.1200/JCO.2008.21.3553
   PubMedGoogle Scholar
• Schilder, C.M., Seynaeve, C., Linn, S.C., Boogerd, W., Beex, L.V., Gundy, C.M., … Schagen, S.B. (2012). Self-reported cognitive functioning in postmenopausal breast cancer patients before and during endocrine treatment: Findings from the neuropsychological TEAM side-study. Psycho-Oncology, 21, 479–487. doi: 10.1002/pon.1928
   PubMed Web of Science ®Google Scholar
• Seigers, R. & Fardell, J.E. (2011). Neurobiological basis of chemotherapy-induced cognitive impairment: A review of rodent research. Neuroscience and Biobehavioral Reviews, 35, 729–741.
   PubMed Web of Science ®Google Scholar
• Sherwin, B.B. (2012). Estrogen and cognitive functioning in women: Lessons we have learned. Behavioral Neuroscience, 126, 123–127. doi: 10.1037/a0025539
   PubMed Web of Science ®Google Scholar
• Shilling, V., Jenkins, V., Morris, R., Deutsch, G. & Bloomfield, D. (2005). The effects of adjuvant chemotherapy on cognition in women with breast cancer – Preliminary results of an observational longitudinal study. Breast, 14, 142–150. doi: 10.1016/j.breast.2004.10.004
   PubMed Web of Science ®Google Scholar
• Small, B.J., Rawson, K.S., Walsh, E., Jim, H.S., Hughes, T.F., Iser, L., … Jacobsen, P.B. (2011). Catechol-O-methyltransferase (COMT) genotype modulates cancer treatment-related cognitive deficits in breast cancer survivors. Cancer, 117, 1369–1376.
   PubMed Web of Science ®Google Scholar
• Sprod, L.K., Mohile, S.G., Demark-Wahnefried, W., Janelsins, M.C., Peppone, L.J., Morrow, G.R., … Mustian, K.M. (2012). Exercise and cancer treatment symptoms in 408 newly diagnosed older cancer patients. Journal of Geriatric Oncology, 3, 90–97. doi: 10.1016/j.jgo.2012.01.002
   PubMedGoogle Scholar
• Stewart, A., Collins, B., Mackenzie, J., Tomiak, E., Verma, S. & Bielajew, C. (2008). The cognitive effects of adjuvant chemotherapy in early stage breast cancer: A prospective study. Psycho-Oncology, 17, 122–130. doi: 10.1002/pon.1210
   PubMed Web of Science ®Google Scholar
• Swayampakula, A.K., Alkhouri, N., Haut, M.W. & Abraham, J. (2007). Cognitive impairment with significant brain parenchymal volume loss following standard adjuvant chemotherapy in a patient with breast cancer. Clinical Advances in Hematology and Oncology, 5, 985–987; discussion 987–988.
   PubMedGoogle Scholar
• Tager, F.A., McKinley, P.S., Schnabel, F.R., El-Tamer, M., Cheung, Y.K.K., Fang, Y.X., … Hershman, D.L. (2011). The cognitive effects of chemotherapy in post-menopausal breast cancer patients: A controlled longitudinal study [Erratum]. (2010, 123, 25–34). Breast Cancer Research and Treatment, 126, 271–272. doi: 10.1007/s10549-009-0684-7
   Google Scholar
• Tangpong, J., Cole, M.P., Sultana, R., Estus, S., Vore, M., St Clair, W., … Butterfield, D.A. (2007). Adriamycin-mediated nitration of manganese superoxide dismutase in the central nervous system: Insight into the mechanism of chemobrain. Journal of Neurochemistry, 100, 191–201. doi: JNC4179 p. 10.1111/j.1471-4159.2006.04179.x
   PubMed Web of Science ®Google Scholar
• Tangpong, J., Cole, M.P., Sultana, R., Joshi, G., Estus, S., Vore, M., … Butterfield, D.A. (2006). Adriamycin-induced, TNF-alpha-mediated central nervous system toxicity. Neurobiology of Disease, 23, 127–139. doi: 10.1016/j.nbd.2006. 02.013
   PubMed Web of Science ®Google Scholar
• van Dam, F.S., Schagen, S.B., Muller, M.J., Boogerd, W., vd Wall, E., Droogleever Fortuyn, M.E. & Rodenhuis, S. (1998). Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: High-dose versus standard-dose chemotherapy. Journal of the National Cancer Institute, 90, 210–218.
   PubMed Web of Science ®Google Scholar
• Vardy, J., Dhillon, H., Pond, G.R., Rourke, S., Xu, W., Renton, C., … Tannock, I.F. (2012). Cognitive function in colorectal cancer patients: Interim analysis of a longitudinal prospective study. J Clin Oncol Supp. abs. 9021, [Abstract].
   Google Scholar
• Vardy, J., Wong, K., Yi, Q.L., Park, A., Maruff, P., Wagner, L. & Tannock, I.F. (2006). Assessing cognitive function in cancer patients. Supportive Care in Cancer, 14, 1111–1118. doi: 10.1007/s00520-006-0037-6
   PubMed Web of Science ®Google Scholar
• Vardy, J.L., Booth, C., Pond, G.R., Zhang, H., Dhillon, S., Clarke, S.J. & Tannock, I.F. (2007). Cytokine levels in patients with colorectal cancer and breast cancer and their relationship to fatigue and cognitive function. [Abstract 9070]. Journal of Clinical Oncology, ASCO Proceedings Supplement.
   Google Scholar
• Vearncombe, K.J., Rolfe, M., Wright, M., Pachana, N.A., Andrew, B. & Beadle, G. (2009). Predictors of cognitive decline after chemotherapy in breast cancer patients. Journal of the International Neuropsychological Society, 15, 951–962. doi: S1355617709990567 p.10.1017/S1355617709990567
   PubMed Web of Science ®Google Scholar
• Villani, F., Busia, A., Villani, M., Vismara, C., Viviani, S. & Bonfante, V. (2008). Serum cytokine in response to chemo-radiotherapy for Hodgkin's disease. Tumori, 94, 803–808.
   PubMed Web of Science ®Google Scholar
• Von Ah, D., Carpenter, J.S., Saykin, A., Monahan, P., Wu, J., Yu, M., … Unverzagt, F. (2012). Advanced cognitive training for breast cancer survivors: A randomized controlled trial. Breast Cancer Research and Treatment, 135, 799–809. doi: 10.1007/s10549-012-2210-6
   PubMed Web of Science ®Google Scholar
• Wagner, L., Sweet, J., Butt, Z., Lai, J., Cella, D. (2009). Measuring patient self-reported cognitive function: Development of the Functional Assessment of Cancer Therapy – Cognitive Function instrument. Journal of Supportive Oncology, 7, 32–39.
   Google Scholar
• Wefel, J.S., Lenzi, R., Theriault, R.L., Davis, R.N. & Meyers, C.A. (2004). The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: Results of a prospective, randomized, longitudinal trial. Cancer, 100, 2292–2299. doi: 10.1002/cncr.20272
   PubMed Web of Science ®Google Scholar
• Wefel, J.S., Saleeba, A.K., Buzdar, A.U. & Meyers, C.A. (2010). Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer, 116, 3348–3356. doi: 10.1002/cncr.25098
   PubMed Web of Science ®Google Scholar
• Wefel, J.S., Vardy, J., Ahles, T. & Schagen, S.B. (2011). International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncology, 12, 703–708. doi: 10.1016/S1470-2045(10) 70294-1
   PubMed Web of Science ®Google Scholar
• Wieneke, M.H. & Dienst, E.R. (1995). Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psycho-Oncology, 4, 61–66.
   Web of Science ®Google Scholar
• Yoshikawa, E., Matsuoka, Y., Inagaki, M., Nakano, T., Akechi, T., Kobayakawa, M., … Uchitomi, Y. (2005). No adverse effects of adjuvant chemotherapy on hippocampal volume in Japanese breast cancer survivors. Breast Cancer Research and Treatment, 92, 81–84. doi: 10.1007/s10549-005-1412-6.
   PubMed Web of Science ®Google Scholar